PT3388422T - Dispersão sólida amorfa de um antagonista dos recetores de hormonas libertadoras de gonadotrofina disponível por via oral - Google Patents
Dispersão sólida amorfa de um antagonista dos recetores de hormonas libertadoras de gonadotrofina disponível por via oralInfo
- Publication number
- PT3388422T PT3388422T PT171665375T PT17166537T PT3388422T PT 3388422 T PT3388422 T PT 3388422T PT 171665375 T PT171665375 T PT 171665375T PT 17166537 T PT17166537 T PT 17166537T PT 3388422 T PT3388422 T PT 3388422T
- Authority
- PT
- Portugal
- Prior art keywords
- receptor antagonist
- solid dispersion
- amorphous solid
- hormone receptor
- releasing hormone
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dispersion Chemistry (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP17166537.5A EP3388422B1 (en) | 2017-04-13 | 2017-04-13 | Amorphous solid dispersion of an orally available gonadotropin-releasing hormone receptor antagonist |
Publications (1)
Publication Number | Publication Date |
---|---|
PT3388422T true PT3388422T (pt) | 2020-02-18 |
Family
ID=58547423
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT171665375T PT3388422T (pt) | 2017-04-13 | 2017-04-13 | Dispersão sólida amorfa de um antagonista dos recetores de hormonas libertadoras de gonadotrofina disponível por via oral |
Country Status (6)
Country | Link |
---|---|
US (1) | US10966979B2 (pt) |
EP (1) | EP3388422B1 (pt) |
CA (1) | CA3057950C (pt) |
ES (1) | ES2770132T3 (pt) |
PT (1) | PT3388422T (pt) |
WO (1) | WO2018189213A1 (pt) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8765948B2 (en) | 2007-11-07 | 2014-07-01 | Neurocrine Biosciences, Inc. | Processes for the preparation of uracil derivatives |
AU2018317472A1 (en) * | 2017-08-18 | 2020-03-05 | Abbvie Inc. | Pharmaceutical formulations for treating endometriosis, uterine fibroids, polycystic ovary syndrome or adenomyosis |
CN113912552A (zh) * | 2020-07-09 | 2022-01-11 | 成都苑东生物制药股份有限公司 | 一种噁拉戈利钠无定型的制备方法 |
US11273128B1 (en) | 2021-04-15 | 2022-03-15 | Sandoz Ag | Elagolix formulation |
CN117545484A (zh) * | 2021-04-21 | 2024-02-09 | 上海启晟合研医药科技有限公司 | 一种噁拉戈利钠组合物 |
EP4279075A1 (en) | 2022-05-12 | 2023-11-22 | Zaklady Farmaceutyczne Polpharma S.A. | A pharmaceutical composition comprising elagolix |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MXPA06000297A (es) | 2003-07-07 | 2006-03-28 | Neurocrine Biosciences Inc | Derivados de pirimidina-2,4-diona como antagonistas del receptor de la hormona de liberacion de gonadotropina. |
US8765948B2 (en) | 2007-11-07 | 2014-07-01 | Neurocrine Biosciences, Inc. | Processes for the preparation of uracil derivatives |
US9949973B2 (en) | 2015-07-07 | 2018-04-24 | Abbvie Inc. | Acoustic mixing for auto granulation |
US20190321363A1 (en) * | 2016-06-20 | 2019-10-24 | Dr. Reddy's Laboratories Limited | Process for the preparation of elagolix sodium and its polymorph |
-
2017
- 2017-04-13 PT PT171665375T patent/PT3388422T/pt unknown
- 2017-04-13 EP EP17166537.5A patent/EP3388422B1/en active Active
- 2017-04-13 ES ES17166537T patent/ES2770132T3/es active Active
-
2018
- 2018-04-11 US US16/498,525 patent/US10966979B2/en active Active
- 2018-04-11 WO PCT/EP2018/059219 patent/WO2018189213A1/en active Application Filing
- 2018-04-11 CA CA3057950A patent/CA3057950C/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CA3057950C (en) | 2020-09-08 |
WO2018189213A1 (en) | 2018-10-18 |
US20200022980A1 (en) | 2020-01-23 |
EP3388422A1 (en) | 2018-10-17 |
EP3388422B1 (en) | 2019-11-20 |
US10966979B2 (en) | 2021-04-06 |
CA3057950A1 (en) | 2018-10-18 |
ES2770132T3 (es) | 2020-06-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PT3388422T (pt) | Dispersão sólida amorfa de um antagonista dos recetores de hormonas libertadoras de gonadotrofina disponível por via oral | |
EP3573602A4 (en) | DOSAGE FORMS OF CONTROLLED RELEASE AT SPECIFIC GASTROINTESTINAL SITES | |
EP3650449A4 (en) | FXR RECEPTOR AGONIST | |
IL260307A (en) | Substituted thiohydantoin derivatives as androgen receptor antagonists | |
IL284005A (en) | Glucocorticoid receptor inhibitors | |
EP3628005A4 (en) | CORTICOTROPIN RELEASE FACTOR RECEPTOR ANTAGONISTS | |
SG11202001340VA (en) | Quinoxaline derivatives as adenosine receptor antagonists | |
EP3594221A4 (en) | GPR84 RECEPTOR ANTAGONISTS AND USES THEREOF | |
EP3666772A4 (en) | DIARYLTHIOHYDANTOIN COMPOUND AS ANDROGEN RECEPTOR ANTAGONIST | |
SG11202009981RA (en) | Solid forms and formulations comprising a glucocorticoid receptor antagonist and uses thereof | |
EP3703694A4 (en) | MEDICINES ANTAGONISTS OF OPIOID RECEPTORS | |
IL271694A (en) | Novel uses of a pure 6HT–5 receptor antagonist | |
HK1258023A1 (zh) | 純5-ht6受體拮抗劑與nmda受體拮抗劑的組合 | |
EP3350167A4 (en) | Androgen receptor Antagonist | |
HUE055891T2 (hu) | A gonadotropint felszabadító hormon (GNRH) receptor antagonista kristályos formája és annak elõállítási módja | |
EP3406614A4 (en) | OPIOID RECEPTOR ANTAGONIST CONJUGATE AND USE THEREOF | |
PT3774259T (pt) | Dispositivo e método para preparação de microesferas expandidas | |
GB201816639D0 (en) | GLP-1 Receptor Antagonist | |
HK1247105A1 (zh) | Mu類鴉片受體拮抗劑與類鴉片藥劑的組合劑型 | |
PT3620454T (pt) | Derivado de ácido carboxílico como antagonista do recetor at2r | |
IL284081A (en) | Somatostatin receptor antagonistic compounds and methods of using them | |
SG11202106401UA (en) | Estrogen receptor antagonist | |
EP3165522A4 (en) | Cyclopropyl unsaturated quinoline compound used as leukotriene receptor antagonist and use | |
EP3388423A4 (en) | NK1 RECEPTOR ANTAGONIST | |
GB201700238D0 (en) | Prodrugs of an angiotensin receptor agonist |